Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
(WorldNews Health)

· More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities; urgent need for therapeutic strategies to prevent COVID-19 in this vulnerable population · First-of-its-kind study will enroll up to 2,400 residents and staff at long-term care facilities; will utilize customized mobile research units to conduct the study on-site BASINGSTOKE, August 3, 2020 – Eli Lilly and Company today announced the initiation of BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care...